SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Summary

This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

Timeline

Start

2018-05-29

Primary completion

2019-06-30

Completion

2021-06

Drugs

Indications